
Phase 3 OASIZ-301 data at ACR 2026 show dazodalibep lowered systemic activity in Sjögren disease, with dryness gains at the every-4-weeks dose.
Test your knowledge of the March 2024 issue of AJMC with a quick quiz!
How did at-home HbA1c test kits affect rates of testing in patients with type 2 diabetes?






